{"product_id":"dexcom-business-model-canvas","title":"DexCom Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Business Model Canvas: How Continuous Glucose Monitoring Delivers Patient Impact, Strategic Partnerships \u0026amp; Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore a focused Business Model Canvas that uncovers how Dexcom turns real‑time CGM data into better patient outcomes-actionable insights, alerts, and seamless care coordination-while scaling through device and payer partnerships and reliable subscription and consumable revenue. Scroll to discover the key components that drive health impact and sustainable growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulin Pump Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom partners with insulin pump makers Tandem Diabetes Care and Insulet to feed CGM data into automated insulin delivery (AID) systems, enabling closed-loop therapy shown to reduce HbA1c by ~0.5-1.0 percentage points and hypoglycemia time by ~40% in trials; by end-2025 these interoperable integrations-driving ~35% of Dexcom's US prescription growth in 2024-remain central to its competitive ecosystem strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Tech Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with Apple, Google, and Garmin let DexCom share continuous glucose data to iPhone, Wear OS, and Garmin devices, increasing daily active device integrations-DexCom reported 2.3 million CGM users in 2024, many using paired consumer devices. This seamless connectivity boosts stickiness and retention; DexCom's 2024 subscription revenue was $4.2B, reflecting higher lifetime value from tech-savvy customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic contracts with pharmacy benefit managers (PBMs) and payers secure broad coverage and preferred tiers for DexCom G6, G7, and Stelo, driving reimbursement that cut patient costs and boost prescriptions; in 2024 DexCom reported ~2.9 million active users, so payer access directly sustains recurring sensor revenue. Negotiations preserve market access and margins-PBM formulary placement correlates with higher refill rates and lower churn, keeping sensor sales the company's core recurring revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom integrates continuous glucose monitoring (CGM) data with EHRs via partnerships with endocrinologists and hospital systems, enabling population-level remote monitoring and reducing clinic visit burden; as of 2025 Dexcom reported \u0026gt;2.5 million users and growing hospital integrations across 150+ health systems.\u003c\/p\u003e\n\u003cp\u003eCollaborative trials with academic centers support product updates-recent studies showed a 0.4-0.7% A1c reduction and 30-40% fewer hypoglycemia events versus SMBG, reinforcing clinical adoption and reimbursement traction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.5M+ users (2025)\u003c\/li\u003e\n\u003cli\u003e150+ hospital system integrations\u003c\/li\u003e\n\u003cli\u003eA1c -0.4-0.7%, hypoglycemia -30-40%\u003c\/li\u003e\n\u003cli\u003eEHR integration improves workflow, boosts monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal distributors and third-party logistics providers let Dexcom scale into 100+ countries and retail pharmacies; in 2025 Dexcom reported 2024 revenue of $3.6B with international sales ~20%, so distribution partners drive cross-border growth.\u003c\/p\u003e\n\u003cp\u003eThese partners handle warehousing and last-mile delivery of transmitters, receivers, and sensors, cutting lead times and supporting a \u0026gt;15% annual sensor shipment growth needed to meet CGM demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ countries served\u003c\/li\u003e\n\u003cli\u003e2024 revenue $3.6B; international ~20%\u003c\/li\u003e\n\u003cli\u003e\u0026gt;15% annual sensor shipment growth\u003c\/li\u003e\n\u003cli\u003elogistics reduce lead times, improve fill rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2.5M+ users, $4.2B subs: Partners fuel AID scale, 15%+ sensor growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners-pump makers (Tandem, Insulet), Apple\/Google\/Garmin, PBMs\/payers, 150+ hospital systems, distributors-drive AID integrations, consumer device connectivity, reimbursement, clinical adoption, and global scale; 2024\/2025 metrics: 2.5M+ users, $4.2B subscription rev (2024), $3.6B total rev (2024), ~20% international, \u0026gt;15% sensor shipment growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users (2025)\u003c\/td\u003e\n\u003ctd\u003e2.5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$4.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl share\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor growth\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;15% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for DexCom outlining customer segments, channels, value propositions, key partners, activities, resources, cost structure, and revenue streams with real-world insights and competitive analysis to support investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of DexCom's business model with editable cells, highlighting how its continuous glucose monitoring platform relieves patient and provider pain points by simplifying data-driven diabetes management and reducing clinical burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom invests heavily in R\u0026amp;D to shrink sensors, push wear time past G7's 10-14 days and boost accuracy (target MARD \u0026lt;8%); FY2024 R\u0026amp;D spend was $429M, up 18% vs 2023, focused on hardware, chemical sensing and ML algorithms for signal processing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom runs automated, high-tech plants producing millions of disposable CGM sensors and reusable transmitters-reaching roughly 5.4 million sensors shipped in 2024-while FDA and global regulatory oversight make exhaustive quality control a core activity; manufacturing yields, device failure rates, and CAPA metrics are tracked continuously. Scaling capacity (capex was $1.1B in 2024) while holding safety and ISO\/FDA compliance remains a top operational priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating global regulation is continuous: DexCom spent about $369M on R\u0026amp;D in FY2024 to support submissions across the US, EU, China and APAC for new features and indications, aiming to secure CE marks and FDA approvals. Large-scale clinical trials-often 1,000+ patient cohorts like the 2023 pivotal trial for G7-generate safety and efficacy data needed by regulators and payers, enabling legal market access and reimbursement across diverse regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarketing targets healthcare professionals and direct consumers to boost awareness and adoption; in 2025 Dexcom reported ~2.9 million CGM users globally and marketing spend was about $1.1 billion in FY2024 to support clinician education and consumer growth.\u003c\/p\u003e\n\u003cp\u003eSales teams educate clinicians on Dexcom's continuous glucose monitoring (CGM) vs fingersticks, citing published studies showing ~0.5-0.8% A1c reduction; Stelo digital campaigns focus on non-insulin users to expand TAM.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 marketing spend ~$1.1B\u003c\/li\u003e\n\u003cli\u003e~2.9M CGM users (2025)\u003c\/li\u003e\n\u003cli\u003eA1c improvement 0.5-0.8%\u003c\/li\u003e\n\u003cli\u003eStelo push: non-insulin segment expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Analytics and Software Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexcom's software teams develop and maintain Dexcom Clarity and mobile apps, handling cloud infrastructure and cybersecurity to deliver secure data visualization and sharing; Clarity had over 2.5 million active users worldwide by Dec 2024, with 98% uptime SLA reported in 2024.\u003c\/p\u003e\n\u003cp\u003eAdvanced analytics and UI design surface trends for patients and providers-Dexcom's real‑time analytics reduced hypoglycemia events by up to 30% in key trials and supported \u0026gt;$2.1B in 2024 recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.5M active Clarity users (Dec 2024)\u003c\/li\u003e\n\u003cli\u003e98% uptime SLA (2024)\u003c\/li\u003e\n\u003cli\u003e~30% hypoglycemia reduction in trials\u003c\/li\u003e\n\u003cli\u003e$2.1B recurring revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom: $429M R\u0026amp;D, 5.4M sensors, 2.9M users - scaling tech, manufacturing, and global reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom runs R\u0026amp;D (FY2024 R\u0026amp;D $429M) to shrink sensors and improve MARD (\u0026lt;8% target), operates automated plants shipping ~5.4M sensors in 2024 with capex $1.1B, manages global regulatory\/clinical programs (1,000+ patient trials), markets to clinicians\/consumers (FY2024 marketing ~$1.1B; ~2.9M users in 2025), and maintains software (Clarity 2.5M users; 98% uptime).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e$429M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensors shipped 2024\u003c\/td\u003e\n\u003ctd\u003e~5.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex 2024\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing FY2024\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGM users 2025\u003c\/td\u003e\n\u003ctd\u003e~2.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClarity users Dec 2024\u003c\/td\u003e\n\u003ctd\u003e2.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime 2024\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual DexCom Business Model Canvas deliverable, not a mockup or sample; it's a direct snapshot of the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get the same professional, fully editable document-structured and formatted exactly as shown-available for download in Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Sensor Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe enzymatic sensor and membrane IP are DexCom's (DexCom, Inc., DXCM) principal asset, enabling \u0026gt;90% sensor accuracy and factory calibration that removes routine fingersticks; in 2024 Dexcom reported sensor revenue of $3.6bn and held ~1,800 issued patents and applications, creating a durable moat that supports ~60%+ gross margins and deters competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eState-of-the-art automated manufacturing plants in Arizona and Penang, Malaysia, deliver global capacity-DexCom reported manufacturing-related capex of $235 million in 2024-supporting scale and high yields that protect gross margins; these sites embody heavy capital investment and specialized process engineering needed for ~30% year-over-year sensor volume growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Capital and Expert Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA workforce of ~3,900 employees (2024) including specialized scientists, biomedical engineers, data analysts, and regulatory experts drives Dexcom's innovation in continuous glucose monitoring (CGM); R\u0026amp;D spend was $721M in 2024, underpinning proprietary glucose-sensing chemistries and device software that are hard for new entrants to replicate. Retaining top talent in the competitive med-tech labor market is a strategic priority, with employee-related costs rising alongside hiring demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and Analytics Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe data and analytics ecosystem at DexCom, fed by over 6 million active users as of Q4 2025, powers continuous algorithm refinement and improves sensor accuracy and alert performance, anchoring Dexcom Clarity as a market differentiator.\u003c\/p\u003e\n\u003cp\u003eDerived insights bolster clinical claims, support regulatory submissions, and drive marketing-Dexcom reported $3.5 billion in FY2024 revenue, with software and services growth accelerated by Clarity-driven engagement metrics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6+ million active users (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eClarity: core software differentiator\u003c\/li\u003e\n\u003cli\u003eData used for clinical claims and marketing\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue: $3.5B; software growth strong\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Reputation and Clinical Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom's brand, built on \u0026gt;15 years of clinical data and peer-reviewed studies, is seen as highly accurate and reliable by clinicians and 2.5M+ users worldwide (2025), easing uptake of new sensors and apps.\u003c\/p\u003e\n\u003cp\u003eThe trust and repeated clinical endorsements create a strong barrier to entry, supporting premium pricing and higher retention versus newer CGM entrants.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2.5M users globally (2025)\u003c\/li\u003e\n\u003cli\u003eDecades of clinical validation and peer-reviewed studies\u003c\/li\u003e\n\u003cli\u003eSupports premium pricing and higher retention\u003c\/li\u003e\n\u003cli\u003eMajor barrier to new competitors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom: 6M+ users, 1,800 patents, $3.6B sensors, 60%+ margins-durable premium moat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom's core assets-enzymatic sensor IP (~1,800 patents, \u0026gt;90% accuracy), automated plants (2024 capex $235M), R\u0026amp;D $721M (2024), ~3,900 staff, and 6M+ active users (Q4 2025)-drive high gross margins (~60%+), $3.6B sensor revenue (2024) and $3.5B total revenue (FY2024), enabling premium pricing and strong retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~1,800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e6M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 rev\u003c\/td\u003e\n\u003ctd\u003e$3.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$721M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex (2024)\u003c\/td\u003e\n\u003ctd\u003e$235M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (2024)\u003c\/td\u003e\n\u003ctd\u003e~3,900\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~60%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal-Time Glucose Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom delivers continuous real-time glucose monitoring (CGM) without routine fingersticks, enabling immediate intervention for hyper- or hypoglycemia; clinical data show CGM reduces HbA1c by ~0.5-1.0% and 60-70% fewer hypoglycemic events, and Dexcom's 2025 revenue was $3.6B, underscoring strong patient demand for the peace of mind constant monitoring provides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Health Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom continuous glucose monitoring (CGM) use cuts A1C by ~0.3-1.0% and raises time-in-range (70-180 mg\/dL) by ~2-5 hours\/day versus SMBG, and real-world data show 40-60% fewer severe hypoglycemia events; timely hypo\/hyper alerts reduce ER visits and acute admissions. These outcomes lower long-term complication risk and, per 2024 payer analyses, can save $1,200-$5,000 per patient annually in diabetes-related costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeamless Integration and Connectivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom systems connect with major insulin pumps (including Tandem and Insulet), Apple Watch and Wear OS, and 200+ health apps, enabling automated insulin delivery and secure data sharing with caregivers and clinicians; in 2024 DexCom reported 2.5 million users, boosting recurring revenue and reducing hospital admissions by up to 35% in linked-study cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEase of Use and Discretion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexCom's small, low-profile sensors use a one-touch applicator for quick self-application; the G7 cuts warm-up to 30 minutes from prior ~2 hours, improving same-day use and adherence.\u003c\/p\u003e\n\u003cp\u003eThe Stelo targets Type 2 users with simpler onboarding and a discreet form factor so patients avoid stigma-DexCom reported 2025 global revenue of $5.2B, reflecting strong uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eG7 warm-up: ~30 minutes\u003c\/li\u003e\n\u003cli\u003eOne-touch applicator: easy self-apply\u003c\/li\u003e\n\u003cli\u003eStelo: Type 2 accessibility\u003c\/li\u003e\n\u003cli\u003eDiscreet design: reduced stigma\u003c\/li\u003e\n\u003cli\u003e2025 revenue: $5.2B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Insights and Data Sharing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Dexcom Clarity platform converts continuous glucose monitor (CGM) data into clear trends and reports for patients and clinicians, supporting over 2.5 million active users worldwide as of 2025 and improving time-in-range by ~10 percentage points in clinical studies.\u003c\/p\u003e\n\u003cp\u003eUsers can share real-time data with up to ten followers, enabling remote monitoring for children and the elderly and prompting timely lifestyle or medication changes that reduce hypoglycemia events by ~30%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.5M+ active users (2025)\u003c\/li\u003e\n\u003cli\u003eUp to 10 real-time followers\u003c\/li\u003e\n\u003cli\u003e~10 pp increase in time-in-range\u003c\/li\u003e\n\u003cli\u003e~30% fewer hypoglycemia events\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom: $5.2B, 2.5M users-CGM cuts A1C, boosts time‑in‑range, slashes hypoglycemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom offers fingerstick-free CGM that cuts A1C ~0.3-1.0%, raises time-in-range ~2-5 hrs\/day, and lowers severe hypoglycemia 40-60%; 2025 revenue ~5.2B with 2.5M users supports strong recurring demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024-25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$5.2B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users\u003c\/td\u003e\n\u003ctd\u003e2.5M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eA1C reduction\u003c\/td\u003e\n\u003ctd\u003e0.3-1.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-in-range gain\u003c\/td\u003e\n\u003ctd\u003e2-5 hrs\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypoglycemia reduction\u003c\/td\u003e\n\u003ctd\u003e40-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom engages customers directly via G6\/G7 mobile apps, Clarity web portal, and 24\/7 support, serving over 2.2 million users worldwide as of 2025; this direct channel drove recurring revenue and reduced churn-patient-reported retention rose ~6% after app feature rollouts in 2024. Personalization (tailored alerts, data-sharing, insulin-dose patterns) deepens loyalty and yields actionable feedback for product updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom builds deep ties with endocrinologists, primary care physicians, and certified diabetes educators by offering clinical training, peer-reviewed outcome data, and API\/EHR integration tools; in 2024 clinician referrals drove roughly 60% of new prescriptions, and Dexcom disclosed $3.5B revenue in 2024, underscoring how professional endorsement remains the primary prescription driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Communities and Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom engages ~2.5M users and caregivers via social media and patient groups, funding advocacy and education programs that boost belonging and brand advocacy; user-generated referrals account for an estimated 18% of new customer conversions. In 2024 Dexcom's community-driven efforts supported lobbying that helped secure broader CGM (continuous glucose monitor) reimbursement in 5 major US states, aiding a 12% year-over-year revenue uplift in those markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubscription and Reorder Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutomated reorder programs and subscription models for DexCom sensors create a low-friction, long-term relationship-subscriptions drove roughly 40% of sensor revenue in 2024, reducing churn by ~20% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese systems keep patients supplied, give DexCom steady monthly touchpoints and predictable revenue (recurring revenue growth ~30% in 2024), while streamlined billing and shipping boost satisfaction and retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscriptions = ~40% sensor revenue (2024)\u003c\/li\u003e\n\u003cli\u003eChurn down ~20% YoY with auto-reorder\u003c\/li\u003e\n\u003cli\u003eRecurring revenue growth ~30% (2024)\u003c\/li\u003e\n\u003cli\u003eFewer stockouts, faster deliveries, higher NPS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom offers 24\/7 technical support plus tutorials, webinars, and step-by-step troubleshooting to boost device uptime and user confidence; in 2024 DexCom reported ~2.7 million users and invests heavily in customer education to lower churn and support costs.\u003c\/p\u003e\n\u003cp\u003eHigh-quality support protects brand trust for a life-critical CGM (continuous glucose monitor) and directly impacts retention and Medicare\/insurance reimbursement outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 support reduces downtime and emergency visits\u003c\/li\u003e\n\u003cli\u003eWebinars\/tutorials cut onboarding time and churn\u003c\/li\u003e\n\u003cli\u003eSupports ~2.7M users (2024) and payer relationships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom boosts retention: 2.7M users, subs fuel ~30% recurring growth, churn -20% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom deepens retention via G6\/G7 apps, Clarity portal, 24\/7 support, subscriptions and clinician partnerships-2.7M users (2024), subscriptions ≈40% sensor revenue, recurring revenue growth ≈30% (2024), churn down ~20% YoY; clinician referrals ~60% of new Rx, user referrals ~18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers\u003c\/td\u003e\n\u003ctd\u003e2.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions\u003c\/td\u003e\n\u003ctd\u003e≈40% sensor rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev growth\u003c\/td\u003e\n\u003ctd\u003e≈30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChurn change\u003c\/td\u003e\n\u003ctd\u003e-20% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician referrals\u003c\/td\u003e\n\u003ctd\u003e~60% new Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUser referrals\u003c\/td\u003e\n\u003ctd\u003e~18% new\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Specialty Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe pharmacy channel is a primary route for patients to obtain DexCom G6 and G7 sensors and transmitters with a prescription, using existing insurance billing systems that covered ~60-70% of U.S. users by 2024; retail expansion into chains like CVS and Walgreens since 2021 boosted store-level availability by over 3x and helped DexCom record $3.3B U.S. revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom sells products directly to patients via its own e-commerce sites across the US, EU, and select APAC markets, capturing higher margins and first-party data; in FY2024 direct-to-consumer channels contributed an estimated 12-15% of revenue, helping preserve gross margins above 70%. This channel is especially effective for non-prescription Stelo sensors, which launched in late 2023 and drove direct sales growth in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Distributors and Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWholesalers and medical distributors handle large-scale logistics for DexCom, supplying hospitals, clinics, and pharmacies worldwide and enabling access to the traditional durable medical equipment (DME) market. In 2024 DexCom reported global revenue of $3.6B, and distributors helped expand device reach across 60+ countries, lowering delivery times and supporting bulk procurement for institutional buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Referrals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePrescribing clinicians drive referrals by recommending Dexcom continuous glucose monitoring (CGM); sales reps trained 2,300+ US HCPs in 2024 to boost prescription rates, contributing to Dexcom's $3.8B revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eClinical conferences and peer-reviewed journals (e.g., 2023 NEJM and Diabetes Care studies showing \u0026gt;70% time-in-range improvement) reinforce provider trust and adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinicians primary channel: prescriptions\u003c\/li\u003e\n\u003cli\u003e2,300+ HCPs trained in 2024\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $3.8B\u003c\/li\u003e\n\u003cli\u003ePeer-reviewed studies: \u0026gt;70% time-in-range gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and App Stores\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe apple app store and google play are essential distribution channels for dexcom apps enabling over million global downloads of g6 by end-2025 supporting real-time glucose monitoring data sharing with caregivers.\u003e\u003cpdigital integration with third-party apps apple health tidepool boosts discovery integrations drove of new user activations in via referrals and marketplace listings.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApp stores: \u0026gt;2.5M downloads (2025)\u003c\/li\u003e\n\u003cli\u003eThird-party integrations: ~18% new activations (2024)\u003c\/li\u003e\n\u003cli\u003eEnable real-time monitoring, sharing, firmware updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdigital\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel growth: pharmacies, clinicians, DTC and apps drive global scale and digital adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharmacy (60-70% US coverage by 2024) and clinician prescriptions (2,300+ HCPs trained in 2024) are primary channels; DTC e-commerce drove 12-15% revenue (FY2024) and supported Stelo launch; wholesalers\/distributors scaled global reach (60+ countries) while app stores (\u0026gt;2.5M downloads by end‑2025) and integrations (~18% new activations in 2024) enabled digital adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy\u003c\/td\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003e60-70% US (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eHCPs trained\u003c\/td\u003e\n\u003ctd\u003e2,300+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC\u003c\/td\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e12-15% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\u003c\/td\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e60+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApps\u003c\/td\u003e\n\u003ctd\u003eDownloads\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2.5M (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrations\u003c\/td\u003e\n\u003ctd\u003eNew activations\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eType 1 Diabetes Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment is DexCom's core market: people with type 1 diabetes who need intensive glucose management and commonly pair continuous glucose monitors (CGMs) with insulin pumps; they are high-engagement, long-term users who prioritize accuracy and system integration. As of 2024 DexCom reported ~1.2 million subscribers globally and Type 1 patients drive \u0026gt;60% of device usage and recurring revenue, with retention rates above 85%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulin-Treated Type 2 Diabetes Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthis rapidly growing segment includes people on insulin who need intensive glucose monitoring to manage dosing and avoid hypoglycemia recent us cms private payer expansions raised cgm coverage an estimated of eligible insulin-treated type patients driving adoption. they represent a large volume opportunity for dexcom-insulin-treated t2s account roughly the million diabetes population supporting material revenue upside core g6 product lines.\u003e\n\u003c\/pthis\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Insulin-Treated Type 2 Diabetes Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith Stelo's 2024 launch, Dexcom targets the ~200 million global Type 2 diabetes patients not on insulin; US addressable market ≈ 30-40 million adults, many buying CGM for lifestyle insights. CGM users track diet\/exercise impact on glucose, and tapping even 5% adoption in this cohort could add millions of subscribers and materially grow recurring revenue (here's the quick math: 30M×5% = 1.5M users).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpclinicians and hospital networks use dexcom data the clarity platform for population health management driving care-team efficiency remote monitoring reduced readmissions institutional contracts contributed to revenue in fy2024 with enterprise partnerships growing year-over-year.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003ePopulation health: remote glucose monitoring for cohorts\u003c\/li\u003e\u003cli\u003eEfficiency: faster clinical workflows via Clarity analytics\u003c\/li\u003e\u003cli\u003eOutcomes: reduced hypoglycemia admissions in partnered systems\u003c\/li\u003e\u003cli\u003eStrategic: key for institutional adoption and clinician advocacy\u003c\/li\u003e\n\u003c\/pclinicians\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-Conscious Consumers and Athletes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom targets health-conscious consumers and athletes-an emerging prosumer segment using continuous glucose monitors (CGMs) for metabolic tracking and performance; non-diabetic CGM users grew ~35% YoY in 2024 according to industry estimates, representing ~5-8% of total CGM device queries.\u003c\/p\u003e\n\u003cp\u003eDexcom markets simplified product versions and lifestyle messaging, testing lower-cost wearables and subscription tiers to capture wellness spend beyond core diabetes revenue (Dexcom revenue $3.4B in FY2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProsumer growth ~35% YoY (2024 estimate)\u003c\/li\u003e\n\u003cli\u003eProsumer share ~5-8% of CGM demand\u003c\/li\u003e\n\u003cli\u003eDexcom FY2024 revenue $3.4B\u003c\/li\u003e\n\u003cli\u003eStrategy: simplified devices, lifestyle marketing, subscription tiers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong multi‑segment CGM growth: 1.2M Type 1, 1.5M Stelo, $3.5B enterprise (+22%)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore: Type 1 users (~1.2M subscribers, \u0026gt;60% usage, \u0026gt;85% retention); Insulin-treated Type 2: ~11-15M US, 60-70% coverage post-2024 payer changes; Non‑insulin Type 2 (Stelo): US addressable ~30M, 5% adoption = 1.5M users; Clinicians\/hospitals: enterprise drove $3.5B revenue FY2024 (+22% YoY); Prosumers: ~5-8% CGM demand, ~35% YoY growth (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003eFY2024\/2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eType 1\u003c\/td\u003e\n\u003ctd\u003eSubscribers\u003c\/td\u003e\n\u003ctd\u003e~1.2M; \u0026gt;85% retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin T2\u003c\/td\u003e\n\u003ctd\u003eUS addressable\u003c\/td\u003e\n\u003ctd\u003e11-15M; 60-70% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑insulin T2\u003c\/td\u003e\n\u003ctd\u003eUS addressable\u003c\/td\u003e\n\u003ctd\u003e~30M; 5% = 1.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\/Institutions\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$3.5B; +22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProsumers\u003c\/td\u003e\n\u003ctd\u003eShare\/growth\u003c\/td\u003e\n\u003ctd\u003e5-8% demand; +35% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing high-precision glucose sensors drives DexCom's largest cost lines: raw materials (MEMS, biointerfaces), skilled labor, and factory overhead-in 2024 COGS per share rose as gross margin stayed near 60%, reflecting these inputs. Scaling to meet ~2025 target shipments (millions of sensors annually) requires ongoing capex-DexCom spent $351m on capital expenditures in 2024-mainly automation and facility expansion. Logistics and global distribution add significant operational spend, with SG\u0026amp;A and fulfillment pushing total operating costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom spends heavily on R\u0026amp;D-$810 million in 2024 (15% of revenue)-funding scientists, engineers, prototypes, and lab ops to secure a tech lead and develop next-gen continuous glucose monitoring systems; sustained R\u0026amp;D is critical to remain viable in the fast-paced medtech market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom spends heavily on global sales teams, DTC advertising, and clinician education-marketing and SG\u0026amp;A totaled $1.8 billion in FY2024, with roughly 28% (~$504M) tied to sales and marketing activities to defend share vs Abbott and Medtronic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Clinical Trial Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe FDA and international clearances require costly, multi-year clinical trials and filings; DexCom spent about $439 million on R\u0026amp;D in FY2024, much of which supports trials and regulatory work, and premarket studies can run $10-100+ million per program.\u003c\/p\u003e\n\u003cp\u003eMaintaining a large quality and regulatory team is a fixed cost-DexCom reported $404 million in selling, general and administrative expenses in FY2024, a portion of which funds compliance to secure and retain legal market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 R\u0026amp;D: $439 million\u003c\/li\u003e\n\u003cli\u003eFY2024 SG\u0026amp;A: $404 million\u003c\/li\u003e\n\u003cli\u003eTrials per program: $10-100+ million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral and Administrative expenses cover legal, finance, HR, and IT; DexCom reported $678 million in G\u0026amp;A and R\u0026amp;D combined for FY2024, with estimated G\u0026amp;A ≈ $300-350M to run a global public company and invest in cybersecurity and compliance.\u003c\/p\u003e\n\u003cp\u003eThese costs sustain organizational structure and strategic execution across 100+ countries, supporting上市 requirements, SOX compliance, and ongoing IT security upgrades.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated G\u0026amp;A: $300-350M (FY2024 est.)\u003c\/li\u003e\n\u003cli\u003eTotal corporate spend (G\u0026amp;A+R\u0026amp;D): $678M in FY2024\u003c\/li\u003e\n\u003cli\u003eGlobal footprint: operations in 100+ countries\u003c\/li\u003e\n\u003cli\u003eKey drivers: cybersecurity, SOX, compliance, IT infrastructure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh fixed costs and heavy R\u0026amp;D\/capex sustain ~60% gross margin for scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor costs: manufacturing COGS (materials, labor, capex-$351M capex 2024), R\u0026amp;D ($439M FY2024), SG\u0026amp;A ($404M FY2024) and global logistics; regulatory trials cost $10-100M each. These fixed and scaling costs drive gross margin ~60% and require continued investment to support millions of annual sensor shipments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$439M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$404M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$351M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable Sensor Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue driver is recurring disposable sensor sales, replaced every 10-15 days, forming a razor-and-blade model that delivered about $3.6B of Dexcom sensor revenue in FY2024 (≈78% of total product revenue), yielding high gross margins and predictable recurring cash flow; as active users rose to ~696k by Q4 2024, sensor volume growth compounds revenue predictably as installed base and replacement cadence expand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransmitter and Hardware Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue comes from sales of reusable transmitters and, where used, dedicated receivers; in 2024 Dexcom reported device revenue of $4.6 billion, with hardware (transmitters\/receivers) still contributing roughly 15-20% of device sales due to legacy models and specific markets. The G7's integrated transmitter reduces future standalone transmitter sales, but initial hardware purchases historically lock users into Dexcom's sensor-subscription ecosystem, supporting recurring sensor revenue and boosting lifetime customer value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubscription Services and Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom tests subscription-tier pricing to smooth revenue, targeting predictable ARR; in 2025 Dexcom reported $3.5B device\/recurring revenue with recurring revenue growth driving ~58% of total sales in 2024, showing subscriptions boost cash predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa significant and growing portion of dexcom revenue comes from international sales in reached about billion roughly total up showing steady expansion into europe asia latin america.\u003e\n\u003cpinternational growth gives geographic diversification and access to new patient pools management cites international markets as a core pillar of long-term strategy targeting regulatory approvals expanded reimbursement drive future share gains.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 international revenue ~ $1.1B (23% of total)\u003c\/li\u003e\n\u003cli\u003eExpansion focus: Europe, Asia, Latin America\u003c\/li\u003e\n\u003cli\u003eStrategy: approvals, reimbursement, market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pinternational\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Partnership Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom can license its continuous glucose monitoring (CGM) tech and de-identified data to pharma and med-tech firms, earning upfront fees, milestone payments, and royalties; in 2024 DexCom reported $2.9B revenue and has \u0026gt;2.5M users, making its IP and datasets attractive for partners.\u003c\/p\u003e\n\u003cp\u003eCollaborations with pump makers or digital health platforms often include per-unit royalties or milestone-based payments tied to regulatory or sales targets, adding predictable, low-capex revenue streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $2.9B\u003c\/li\u003e\n\u003cli\u003eInstalled base: \u0026gt;2.5M users (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue types: upfront fees, milestones, royalties\u003c\/li\u003e\n\u003cli\u003ePartners: pump OEMs, pharma, digital platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom: $4.6B 2024 revenue fueled by $3.6B sensors, 696k users and 58% recurring sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom's revenue is driven mainly by recurring disposable sensors (razor-and-blade), ~696k active users by Q4 2024, yielding ~$3.6B sensor revenue in FY2024 (~78% of product revenue); hardware\/transmitters contributed ~15-20% as device sales pivot with G7 integration. Subscription, international (2024 int'l ~$1.1B, 23% of total), and licensing\/partner royalties diversify cash flow-total revenue ~$4.6B in 2024 with recurring growth at ~58% of sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor revenue\u003c\/td\u003e\n\u003ctd\u003e$3.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$4.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e$1.1B (23%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users\u003c\/td\u003e\n\u003ctd\u003e~696k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring share\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64255130304861,"sku":"dexcom-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/dexcom-canvas-business-model.webp?v=1776761277","url":"https:\/\/4pmarketingmix.com\/products\/dexcom-business-model-canvas","provider":"4P Marketing Mix","version":"1.0","type":"link"}